CLGN vs. COCH, MLSS, RBOT, LFWD, NTRB, INGN, SMTI, TPST, CVM, and HOOK
Should you be buying CollPlant Biotechnologies stock or one of its competitors? The main competitors of CollPlant Biotechnologies include Envoy Medical (COCH), Milestone Scientific (MLSS), Vicarious Surgical (RBOT), ReWalk Robotics (LFWD), Nutriband (NTRB), Inogen (INGN), Sanara MedTech (SMTI), Tempest Therapeutics (TPST), CEL-SCI (CVM), and Hookipa Pharma (HOOK). These companies are all part of the "medical" sector.
Envoy Medical (NASDAQ:COCH) and CollPlant Biotechnologies (NASDAQ:CLGN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, valuation, community ranking, profitability, analyst recommendations, risk, dividends and earnings.
Envoy Medical currently has a consensus price target of $6.00, suggesting a potential upside of 85.19%. CollPlant Biotechnologies has a consensus price target of $11.00, suggesting a potential upside of 78.86%. Given CollPlant Biotechnologies' higher probable upside, equities research analysts clearly believe Envoy Medical is more favorable than CollPlant Biotechnologies.
Envoy Medical has a net margin of 0.00% compared to Envoy Medical's net margin of -64.05%. CollPlant Biotechnologies' return on equity of 0.00% beat Envoy Medical's return on equity.
CollPlant Biotechnologies has higher revenue and earnings than Envoy Medical.
Envoy Medical has a beta of 2.59, suggesting that its share price is 159% more volatile than the S&P 500. Comparatively, CollPlant Biotechnologies has a beta of 0.23, suggesting that its share price is 77% less volatile than the S&P 500.
In the previous week, Envoy Medical had 4 more articles in the media than CollPlant Biotechnologies. MarketBeat recorded 6 mentions for Envoy Medical and 2 mentions for CollPlant Biotechnologies. Envoy Medical's average media sentiment score of 0.00 beat CollPlant Biotechnologies' score of -0.96 indicating that CollPlant Biotechnologies is being referred to more favorably in the news media.
8.6% of Envoy Medical shares are owned by institutional investors. Comparatively, 21.7% of CollPlant Biotechnologies shares are owned by institutional investors. 0.7% of Envoy Medical shares are owned by insiders. Comparatively, 9.6% of CollPlant Biotechnologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
CollPlant Biotechnologies received 130 more outperform votes than Envoy Medical when rated by MarketBeat users. However, 100.00% of users gave Envoy Medical an outperform vote while only 58.59% of users gave CollPlant Biotechnologies an outperform vote.
Summary
Envoy Medical beats CollPlant Biotechnologies on 8 of the 15 factors compared between the two stocks.
Get CollPlant Biotechnologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for CLGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CLGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CollPlant Biotechnologies Competitors List
Related Companies and Tools
